# Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency

> **NCT06827353** · — · RECRUITING · sponsor: **Centre Hospitalier Universitaire de Nīmes** · enrollment: 300 (estimated)

## Conditions studied

- Ovarian Carcinoma

## Interventions

- **DRUG:** maintenance therapy with bevacizumab
- **DRUG:** maintenance therapy with niraparib

## Key facts

- **NCT ID:** NCT06827353
- **Lead sponsor:** Centre Hospitalier Universitaire de Nīmes
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-01
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06827353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06827353, "Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06827353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*